People with multiple sclerosis (MS) of African descent had higher levels of inflammatory B-cells in the fluid around the brain and spinal cord compared with white MS patients in a small U.S. study. These findings may help to explain why Black people with MS tend to experience a faster…
African-American
Black and Hispanic/Latinx people with multiple sclerosis (MS) in the U.S. tend to have more severe disease, but less access to specialty care, greater diagnostic delays, and poorer outcomes, a review found. Moreover, Blacks are at higher risk than whites of both developing MS and dying from it. These…
A variation in a gene called STK11, previously shown to increase the risk for multiple sclerosis (MS) among Caucasians, is now also linked to a greater likelihood of MS in Black people. In fact, the variation was significantly more common in Black MS patients with secondary progressive MS (SPMS),…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. There is a lack of diversity among neurologists, who are disproportionately white men, but new programs aimed at inclusivity may…
Two genetic variants have been identified by researchers within a genome region previously reported to drive a 1.44-times increased risk of multiple sclerosis (MS) in a group of African Americans with European ancestry. Located in genes involved in immune responses, the variants fully explain the reported European ancestry-associated increased…
Tecfidera (dimethyl fumarate) is as safe and effective in Hispanic/Latino multiple sclerosis (MS) patients as it is in their non-Hispanic and non-Latino peers, three-year data from a real-world study show. These interim findings, based on the largest group of Tecfidera-treated Hispanic and Latino MS patients studied to date, support the therapy’s…
Nearly 3,000 multiple sclerosis (MS) healthcare providers and researchers  convened recently to share their findings regarding the latest developments in the diagnosis and treatment of MS. However, unlike past meetings, this year’s 34th Annual Meeting of the Consortium of MS Centers (CMSC) took place online. Virtual presentations covered the…
African-Americans with relapsing–remitting multiple sclerosis (RRMS) show higher adherence and greater satisfaction when treated with oral Gilenya (fingolimod, by Novartis) than with injectable therapies, according to a new study. The research, “Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A…